Widespread antimonial resistance in anthroponotic visceral leishmaniasis (VL) makes it critical to monitor the susceptibility of prevailing field isolates to upcoming antileishmanials in order to frame the right treatment policies to protect these drugs against development of resistance. We aimed to generate the baseline data on natural in vitro susceptibility to paromomycin and sitamaquine in Leishmania donovani field isolates from VL patients (n = 20) coming from zones of varying sodium antimony gluconate (SAG) resistance. We further monitored nitric oxide (NO) release in infected macrophages treated with these drugs. Field isolates exhibited variable sensitivity to paromomycin and sitamaquine with respective mean 50% effective dose (ED$_{50}$) values ± standard error of the mean (SEM) of 3.9 ± 0.3 μM and 2.1 ± 0.2 μM at the intracellular amastigote stage and 29.8 ± 2.5 μM and 17.7 ± 1.0 μM at the promastigote stage. Susceptibilities at the two parasite stages did not correlate for either drug. Isolates from high SAG resistance zones exhibited significantly lower susceptibility to sitamaquine than those from low SAG resistance zones, while isolates from different zones showed similar susceptibilities to paromomycin. NO release was promoted in L. donovani-infected macrophages upon treatment with paromomycin/sitamaquine. NO inhibitors significantly compromised amastigote killing by sitamaquine, but not by paromomycin. In conclusion, SAG-resistant/sensitive VL isolates were susceptible to both paromomycin and sitamaquine. Paromomycin, exhibiting higher efficacy against SAG-resistant parasites and having a distinct mechanism of action, appears to be a promising drug for combination therapy.

Visceral leishmaniasis (VL), caused by parasitic protozoa of the Leishmania donovani complex, is prevalent in over 70 countries, with an annual incidence of 500,000 and an estimated 59,000 deaths annually (http://www.who.int/Leishmaniasis/en). The heaviest burden of VL (>90%) falls mainly on 5 areas of the world, i.e., India, Nepal, Bangladesh, Brazil, and Africa (8). The Indian subcontinent alone bears 67% of the global VL burden. This has compelled the governments of India, Nepal, and Bangladesh to launch a regional VL elimination program to reduce the annual incidence to less than 1 case per 10,000 individuals by 2015 (3, 34). Presently, treatment is unsatisfactory and is therefore undergoing transition in terms of choice of the first-line treatment. Sodium antimony gluconate (SAG) monotherapy has been the treatment choice for VL for more than 6 decades. However, resistance is now especially well established in areas of endemicity in Bihar, India, where more than half of the VL patients are resistant to SAG (6, 27). The downslope of SAG efficacy has led to the use of alternative antileishmanials, such as amphotericin B and miltefosine. These drugs, although highly effective, have problems of toxicity, high cost, and risk of emergence of resistance, particularly to miltefosine, which has a long half-life (7, 19, 28).

Paromomycin and sitamaquine are new drugs with promising antileishmanial efficacy. Paromomycin is an aminoglycoside antibiotic showing activity against VL (5, 10, 31), with overall cure rates of over 90%. It has successfully completed phase III clinical trials, showing advantages of shorter treatment course, higher safety profile, and low manufacturing cost, making it an affordable therapeutic option under Indian field conditions (29). As a result, it was registered in India in August 2006 and may prove a promising public health tool in the nationwide VL elimination program (26). Sitamaquine, an 8-aminoquinoline, is an oral antileishmanial drug that has completed phase IIa clinical trials with more than 85% cure rates and is currently under phase IIb clinical trials (11, 23, 35). The major limitation for sitamaquine is the nonavailability of sufficient data on the pharmacokinetics of the drug and its metabolites and toxicity concerns, such as renal adverse events and methemoglobinemia in treated kala azar patients. Pharmacokinetic analysis of sitamaquine in dogs indicated that it has relatively high systemic clearance, a large volume of distribution, a relatively short half-life, and low systemic availability (30).

With very few chemotherapeutic alternatives in hand, the primary concern should be to protect the available drugs against development of resistance by formulating and implementing the right policies for administering these drugs. In vitro SAG efficacy is reported to correlate with the clinical outcome (15, 25). The current first-line treatment choices for VL are miltefosine and amphotericin B. However, our study revealed that SAG-resistant isolates have lower in vitro susceptibility to miltefosine and amphotericin B (14). The future of VL chemotherapy now depends on combinatorial treatment that could improve efficacy by reducing the duration or the total drug dosage (and therefore delay resistance) or lower the
toxicity and cost, leading to higher patient compliance. Combination therapy using amphotericin B or its liposomal formulation, along with miltefosine or paromomycin, has shown promising results (32). The determination of the in vitro susceptibility of natural Leishmania parasite populations to new treatment options will help to develop effective control measures. In the present work, we attempted to investigate the susceptibility of L. donovani isolates derived from Indian VL patients hailing from zones with varying degrees of SAG resistance to paromomycin and sitamaquine. Further, in order to understand how these drugs produce their cytotoxic effects on intracellular parasites, we evaluated the effect of paromomycin/sitamaquine treatment on the release of nitric oxide (NO) by L. donovani-infected macrophages (1).

MATERIALS AND METHODS

Patients. To study drug responses, clinical isolates of Leishmania were prepared as described elsewhere (25) from bone marrow aspirates of VL patients reporting to the Department of Medicine, Safdarjung Hospital (SJH), New Delhi, India, between 2001 and 2008. The patients came from Bihar, India, from zones of low and high VL endemicity, which represent, respectively, zones of low resistance (LR) and high resistance (HR) to antimony (Fig. 1) (25). Three patients originated from the neighboring state of West Bengal or Uttar Pradesh (Table 1). All patients received either 20 mg SAG/kg of body weight/day intramuscularly for 30 days or amphotericin B treatment (infusions of 1 mg/kg on alternate days for 1 month). This work was conducted with the approval of the Ethics Committee of SJH, and informed consent was obtained from all patients.

Parasite and cell culture. Parasites were routinely grown as promastigotes in Medium 199 (Sigma) with 10% heat-inactivated fetal calf serum (FCS) (Biological Industries, Israel) at 26°C. The drug susceptibilities of the isolates were determined in less than 6 passages after isolation from patients. Stationary-phase promastigotes harvested on day 6 were used for the promastigote assay and for infection of macrophages. A standard strain of L. donovani (LdAG83) from India (MHOM/IN/83/AG83) was used as the reference parasite throughout the study. All VL isolates were characterized as L. donovani on the basis of species-specific PCR (20).

The murine macrophage cell line J774 A.1 was maintained in RPMI medium (Sigma) containing 1.5 g/liter sodium bicarbonate, 2 g/liter glucose, 12.5 mM l-glutamine, penicillin (100 U/ml), and streptomycin (100 U/ml) supplemented with 10% FCS (Biological Industries, Israel) at 37°C in a humidified atmosphere with 5% CO₂.

Antileishmanial drugs. The antileishmanial drugs, viz., paromomycin sulfate (Sigma Aldrich), sitamaquine (Glaxo Smith Kline, United Kingdom), and SAG (Albert David, India) were employed in this study. Stock solutions of paromomycin and sitamaquine (10 mM each) were freshly prepared in deionized water and filter sterilized. All subsequent dilutions were prepared in the respective culture medium supplemented with 10% FCS on the day of the assay.

Drug susceptibility assay at the promastigote stage. The stationary-phase promastigotes were subjected to a drug-screening assay by plating them at 1 × 10⁶ parasites/well in 24-well plates (TPP, Switzerland) containing either paromomycin (10, 20, 40, 80, 120, and 200 μM) or sitamaquine (10, 15, 20, 30, 50, and 70 μM), along with untreated cells (containing only M199 with 10% FCS) used as a control. The cells were incubated for 72 h at 26°C, and the inhibition of promastigote growth in vitro was assessed by direct counting using a Neubauer chamber under the microscope at ×20 magnification. All the concentrations were tested in triplicate, and experiments were performed in duplicate. The 50% effective dose (ED₅₀) and ED₉₀ values were then calculated in comparison to an untreated control by sigmoidal regression analysis (Origin 6.0, Origin Laboratory).

Drug susceptibility assay at the intracellular amastigote stage. The sensitivity of L. donovani parasites as intracellular amastigotes to paromomycin and sitamaquine was assessed as described elsewhere (24). Briefly, J774A.1 cells (1 × 10⁵ cells/ml) were infected with stationary-stage promastigotes at a ratio of 10:1 (parasites to macrophages) and plated on an 8-chamber Labtek tissue culture slide (Nunc). The slides were incubated for 4 h at 37°C in 5% CO₂. Excess, nonadhered promastigotes were removed by washing the slide, and the macrophages were incubated for 18 to 24 h. Infected cells were reincubated for 48 h, with paromomycin (1, 3, 10, 30, and 50 μM) or sitamaquine (1, 3, 10, and 20 μM) in duplicate. These drugs did not show any cytotoxicity to J774A.1 macrophages at the above concentrations. Macrophages were examined at 48 h for intracellular amastigotes after being stained with Diff-Quik solution (Dade Behring, Switzerland). The L. donovani amastigotes in 100 macrophages were counted at ×100 magnification. The percent killing relative to untreated macrophages was calculated, and the ED₅₀ and the ED₉₀ were determined by sigmoidal regression analysis. These assays were repeated at least in triplicate.

Measurement of nitric oxide accumulation. J774 A.1 macrophages were plated at 2 × 10⁵ cells per well in 24-well plates and infected with LdAG83 (1 macrophage to 10 parasites). After 24 h, noninternalized parasites were removed by washing the plates with chilled RPMI medium. Uninfected and infected macro-
Susceptibilities of the isolates to paromomycin and sitamaquine in comparison to SAG are summarized in Table 1.

(i) Susceptibility to paromomycin. The field isolates showed a wide range of susceptibilities to paromomycin at both the amastigote and promastigote stages. The ED$_{50}$ (mean ± SEM) at the promastigote stage ranged from 15.7 ± 2.2 to 52.7 ± 3.5 μM, while the ED$_{90}$ (mean ± SEM) ranged from 25.0 ± 0.8 to 153.9 ± 3.1 μM. The mean and median ED$_{50}$s for paromomycin at the promastigote stage were 29.8 ± 2.5 μM and 28.3 ± μM, while the mean and median ED$_{90}$s were 71.6 ± 7.7 and 69.8 ± μM, respectively. The amastigotes showed higher susceptibility, with ED$_{50}$s ranging from 1.2 ± 0.01 to 5.9 ± 0.3 μM (mean = 3.9 ± 0.3 μM; median = 4.2 μM) (Table 1). The mean ED$_{50}$s of LR region parasites (3.2 ± 0.5 μM) and HR region parasites (3.4 ± 0.3 μM) were comparable ($P = 0.47$) (Fig. 2).

The antileishmanial activity of paromomycin did not correlate ($r = 0.13; P > 0.05$) at the amastigote and promastigote stages, indicating that intracellular amastigotes are the ideal stage for determining sensitivity to paromomycin.

(ii) Susceptibility to sitamaquine. VL field isolates displayed variable susceptibility to sitamaquine at the promastigote stage, with ED$_{50}$s (mean ± SEM) ranging from 12.3 ± 0.8 to 32.9 ± 1.6 μM and ED$_{90}$s ranging from 27.9 ± 1.0 to 62.5 ± 0.7 μM. The mean ED$_{50}$ for sitamaquine was 17.7 ± 1.0 μM, and the mean ED$_{90}$ was 39.9 ± 2.6 μM (Table 1). The median ED$_{50}$ was determined to be 16.9 μM and the median ED$_{90}$ 35.8 μM.

Susceptibilities at the amastigote stage ranged from 0.6 ± 

![Table 1](http://aac.asm.org/Downloadedfrom)
0.1 to 3.7 ± 0.8 μM, with a mean ED₅₀ of 2.1 ± 0.2 μM and a median ED₅₀ of 2.2 μM. Again, the amastigote stage of the parasite was more susceptible than the promastigote stage, with promastigotes displaying 5- to >35-fold-higher ED₅₀ (Table 1). There was no significant correlation between the susceptibilities at the two stages (r = 0.24; P > 0.05). In vitro studies on the antiparasitic effect of total sitamaquine are assumed to be representative of its metabolites, which are largely unknown.

The isolates from the HR region displayed mean ED₅₀ for sitamaquine (2.5 ± 0.2 μM) significantly higher (P = 0.0195) than those from the LR region (1.5 ± 0.3 μM) (Fig. 2).

**Effects of paromomycin and sitamaquine on the production of NO by infected macrophages.** An increase in NO levels upon paromomycin or sitamaquine treatment was observed in both uninfected and infected macrophages, with the increase higher in infected cells than in uninfected cells (Fig. 3A). Sodium nitrite dilutions (0 to 80 μM) were prepared using RPMI medium with and without phenol red. One hundred microliters of the standard dilutions was mixed with an equal volume of Griess reagent, followed by 15 min of incubation at room temperature, and the absorbance at 540 nm was recorded. Similar experiments were performed for nitrite estimation in uninfected J774 cells exposed to paromomycin/sitamaquine. The presence of phenol red in the medium did not interfere significantly with nitrite determination by the Griess method (not shown).

(i) **Effect of paromomycin on NO release.** Paromomycin-activated macrophages produced NO in a dose-dependent manner, and the percent parasite killing correlated significantly with NO release (r = 0.70; P < 0.05) (Fig. 3A). Further, upon addition of L-NMMA (a NOS inhibitor), a decrease in NO production comparable to that of the control infected cells was observed, while the percent parasite killing did not alter significantly (P = 0.186), suggesting that the activity of paromomycin against L. donovani is not dependent on NO (Fig. 3B).

(ii) **Effect of sitamaquine on NO release.** Sitamaquine treatment induced NO production in a dose-dependent manner in infected macrophages. The percent parasite killing correlated positively with NO release (r = 0.58; P < 0.05). Addition of L-NMMA resulted in a decrease in NO production comparable to that of the control infected cells in sitamaquine-treated macrophages, with a significant decrease in parasite killing (P = 0.019), suggesting that the cytotoxic activity of sitamaquine against L. donovani involves the NO pathway (Fig. 3B).

**DISCUSSION**

The present investigation shows for the first time the natural susceptibility of L. donovani from Indian VL cases to upcoming antileishmanial drugs, paromomycin, and sitamaquine. The study reports the scenario of drug susceptibility in the parasite population currently prevailing in the field and as yet unexposed to these drugs. In the present study, more than 5-fold variations in in vitro susceptibility to these two drugs were observed within field isolates. The variability in drug susceptibility observed among field isolates reflects differences in intrinsic susceptibility that could have an important impact on clinical outcomes in the future.

Sensitivities to paromomycin and sitamaquine have been reported previously only in reference strains of Leishmania (2, 12, 16, 21). The ED₅₀ of L. donovani for sitamaquine has been reported to range from 19.8 to 29.2 μM in the promastigote form (9, 16) and 4.78 to 5.41 μM in intracellular amastigotes (21). Similarly, susceptibility to paromomycin in L. donovani ranged from 6 to 50 μM at the promastigote stage and from 8 to 48.81 μM at the intracellular stage (12, 22).

All VL isolates examined in the study, whether from HR or LR regions, were found to be susceptible to both paromomycin and sitamaquine. In the case of sitamaquine, HR region isolates showed significantly lower susceptibilities than LR isolates, similar to previous observations with miltefosine and amphotericin B (14). On the other hand, parasite isolates from HR and LR zones exhibited similar sensitivity to paromomycin, indicating its potential efficacy in areas where VL is endemic. Paromomycin is a polycationic hydrophilic sugar that specifically possess high affinities for certain portions of RNAs and interferes with protein synthesis (13). Its antileishmanial action involves a change in the mitochondrial membrane potential, ribosomal and respiratory dysfunction, and decreased membrane fluidity, leading to altered drug uptake (12, 17). Comparable paromomycin sensitivities in parasite populations from HR and LR regions further indicates that it has a mechanism of action distinct from those of other antileishmanial drugs currently being used.
The leishmanicidal action of antimonials involves generation of reactive oxygen and NO species and affects the mitogen-activated protein (MAP) kinase pathway (18). Insight into the mechanism of action of paromomycin highlights the role of mitochondrial membrane potential, ribosomes, and respiratory dysfunction. However, much less is known about the mechanism of antileishmanial action of sitamaquine. The present study revealed an increase in NO levels in *L. donovani*-infected macrophages upon sitamaquine and paromomycin treatment, coupled with a marked decrease in the number of amastigotes. The presence of NO inhibitor compromised amastigote killing by sitamaquine, suggesting that its cytotoxic activity against *L. donovani* amastigotes involves the NO pathway. Another well-established aminoquinoline, chloroquine, was shown to induce the expression of inducible nitric oxide synthase and NO production in C6 glioma cells (4).

We observed that amastigotes were invariably more sensitive to paromomycin and sitamaquine, up to 4- to 40-fold and 5- to 35-fold, respectively. The higher paromomycin and sitamaquine susceptibility of intracellular amastigotes than of promastigotes, as in the case of SAG, is suggestive of a stage-specific antileishmanial action of these drugs. Although previous studies have mainly used a *Leishmania* promastigote model for determining drug sensitivity *in vitro*, lack of correlation between the promastigote and amastigote susceptibilities to both paromomycin and sitamaquine observed in the present study established the intracellular amastigote model as more appropriate for susceptibility studies, as has been reported for other antileishmanial reference drugs (33). Paromomycin appears promising, since (i) SAG-resistant and -sensitive field isolates were equally susceptible and (ii) it has a mechanism of action distinct from those of other currently available antileishmanials. In this study, we established that isolates from SAG-responsive and unresponsive patients are susceptible to paromomycin and sitamaquine. Additionally, paromomycin, which has a mechanism of action different from those of existing antileishmanials, would be a useful candidate for combination therapy.

**ACKNOWLEDGMENTS**

We thank GlaxoSmithkline (Greenford, United Kingdom) for providing sitamaquine.

Financial support from the Indian Council of Medical Research, New Delhi, India, is gratefully acknowledged. A.K. and D.K. are grate-
ful to the Council for Scientific and Industrial Research, India, for fellowships. R.S. received financial support from UNESCO (L’Oreal for Women in Science Program). We have no conflict of interest to declare.

REFERENCES